Endometrial Carcinoma – Unmet Need – Detailed, Expanded Analysis: Advanced Or Recurrent Endometrial Carcinoma (US/EU)
Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of advanced or recurrent endometrial carcinoma, for which chemotherapy and hormonal therapy used to be the standard of care. Nevertheless, treatment options are limited in later lines of therapy and there remains a pressing need for more-effective treatments in the advanced or recurrent setting. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior for advanced or recurrent endometrial carcinoma. We also identify potential hidden opportunities emerging therapies could capitalize upon.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions in advanced or recurrent endometrial carcinoma? What are the hidden opportunities that developers could leverage?
- How do key current therapies, such as immune checkpoint inhibitors, perform on key clinical attributes for this patient population?
- What are the greatest unmet needs and most attractive opportunities for advanced or recurrent endometrial carcinoma?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2022
Key companies: Merck & Co., Eisai, GlaxoSmithKline
Key drugs: Keytruda, Lenvima, Jemperli
Table of contents
- Endometrial Carcinoma - Unmet Need - Detailed, Expanded Analysis: Advanced Or Recurrent Endometrial Carcinoma (US/EU)
- Executive summary
- Unmet need - Advanced or recurrent endometrial carcinoma - executive summary - October 2022
- Introduction
- Overview
- Methodology
- Rationale for treatment drivers and goals selection
- Rationale for drug selection
- Products / regimens for advanced or recurrent endometrial carcinoma and rationale for drug selection
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologysts' prescribing decisions in advanced or recurrent endometrial carcinoma
- Importance of efficacy attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: United States
- Importance of efficacy attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: Europe
- Importance of safety and tolerability attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: United States
- Importance of safety and tolerability attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: Europe
- Importance of convenience of administration attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: United States
- Importance of convenience of administration attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: Europe
- Importance of nonclinical factors to prescribing decisions in advanced or recurrent endometrial carcinoma: United States
- Importance of nonclinical factors to prescribing decisions in advanced or recurrent endometrial carcinoma: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in advanced or recurrent endometrial carcinoma: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for advanced or recurrent endometrial carcinoma: United States
- Overall performance of key therapies for advanced or recurrent endometrial carcinoma: Europe
- Mean overall performance of key therapies for advanced or recurrent endometrial carcinoma: United States and Europe
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select efficacy attributes: United States
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select efficacy attributes: Europe
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select safety and tolerability attributes: United States
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select safety and tolerability attributes: Europe
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select convenience of administration attributes: United States
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select convenience of administration attributes: Europe
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select nonclinical attributes: United States
- Relative performance of key therapies for advanced or recurrent endometrial carcinoma across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in advanced or recurrent endometrial carcinoma
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for advanced or recurrent endometrial carcinoma on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for advanced or recurrent endometrial carcinoma on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in advanced or recurrent endometrial carcinoma: United States
- Surveyed medical oncologists' ascribed level of unmet need across key efficacy attributes in advanced or recurrent endometrial carcinoma: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in advanced or recurrent endometrial carcinoma: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in advanced or recurrent endometrial carcinoma: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in advanced or recurrent endometrial carcinoma: United States
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in advanced or recurrent endometrial carcinoma: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key nonclinical factors in advanced or recurrent endometrial carcinoma: United States
- Surveyed medical oncologists' ascribed level of unmet need across key nonclinical factors in advanced or recurrent endometrial carcinoma: Europe
- Key findings: unmet need in advanced or recurrent endometrial carcinoma and related indications
- Surveyed medical oncologists' ascribed level of unmet need in advanced or recurrent endometrial carcinoma and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in advanced or recurrent endometrial carcinoma and related indications: Europe
- Opportunity analysis
- Areas of opportunity in the advanced or recurrent endometrial carcinoma market and emerging therapy insights
- Opportunity: a novel therapy that prolongs overall survival
- Opportunity: a novel therapy that improves progression-free survival
- Opportunity: a novel therapy with a better safety and tolerability profile
- Opportunity: novel biomarkers to select suitable patients for a specific therapy
- Areas of opportunity in the advanced or recurrent endometrial carcinoma market and emerging therapy insights
- Target product profiles
- Assessing drug development opportunities
- Target product profile methodology
- Attributes and attribute levels
- Attribute importance and part-worth utilities
- Second-line advanced or recurrent endometrial carcinoma target product profile: attribute importance
- MEDIAN OVERALL SURVIVAL (MONTHS)
- MEDIAN PROGRESSION-FREE SURVIVAL (MONTHS)
- OBJECTIVE RESPONSE RATE (% OF PATIENTS)
- INCIDENCE OF GRADE 3/4 HEMATOLOGICAL TOXICITIES (% OF PATIENTS)
- INCIDENCE OF GRADE 3/4 GASTROINTESTINAL TOXICITIES (% OF PATIENTS)
- INCIDENCE OF GRADE 3/4 IMMUNE-MEDIATED TOXICITIES (% OF PATIENTS)
- PRICE PER 21-DAY CYCLE
- Conjoint analysis-based simulation of a market scenario
- Second-line advanced or recurrent endometrial carcinoma market simulation: share of preference of target product profiles included in the market scenario
- Second-line advanced or recurrent endometrial carcinoma market simulation: likelihood to prescribe of target product profiles included in the market scenario
- Second-line advanced or recurrent endometrial carcinoma market simulation: target product profiles included in the market scenario
- Appendix
- Key abbreviations
- Bibliography
- Executive summary
Marcos Fernández Alfara, M.Sc., Ph.D., is a research analyst on the Oncology team at Clarivate. He has extensive experience in oncology, with a focus on novel immunotherapies for solid tumors. As part of his doctorate, he developed new strategies to boost immune responses against cancer cells. He obtained his master of science degree in cancer and stem cells from Utrecht University and his doctorate in biomedicine from the Institute for Research in Biomedicine at Barcelona University.
